In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with
type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF …

Importance Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in
patients with type 2 diabetes, heart failure, and chronic kidney disease, but their effect on …

Endothelial dysfunction often precedes the development of cardiovascular diseases,
including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 …

Background Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-
cause mortality when started within 14 days of acute myocardial infarction (AMI). Objectives …

A number of therapies that have been shown to be effective in patients with chronic heart
failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin …

The EMMY trial was a multicentre, investigator-initiated, placebo-controlled, double-blind
trial, which enrolled 476 patients immediately following AMI and the first study demonstrating …

Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been studied in
patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic …

After myocardial infarction (MI), patients with type 2 diabetes have an increased rate of
adverse outcomes, compared to patients without. Diabetes confers a 1.5–2-fold increase in …

Background Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are associated with
cardiovascular benefits. The aim of this systematic review and meta-analysis is to …